Compare ACHV & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACHV | TECX |
|---|---|---|
| Founded | N/A | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 726.5M | 618.9M |
| IPO Year | 2018 | 2018 |
| Metric | ACHV | TECX |
|---|---|---|
| Price | $7.00 | $21.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 10 |
| Target Price | $14.15 | ★ $71.00 |
| AVG Volume (30 Days) | ★ 1.3M | 232.0K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 40.70 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.62 | $15.60 |
| 52 Week High | $8.64 | $39.53 |
| Indicator | ACHV | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 41.70 | 27.20 |
| Support Level | $6.92 | $20.52 |
| Resistance Level | $7.11 | $30.80 |
| Average True Range (ATR) | 0.38 | 1.28 |
| MACD | -0.07 | 0.08 |
| Stochastic Oscillator | 13.10 | 3.91 |
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.